Karyopharm Secures One-Month Debt Extension While Awaiting Xpovio Decision

Karyopharm Therapeutics, facing cash constraints, has negotiated a temporary reprieve on a $15.8 million debt that was due.

Under the agreement, lenders and noteholders will refrain from enforcement actions until mid-October, giving the company about a month to explore financing or strategic options. In return, Karyopharm will issue $20 million of newly created convertible stock as a fee.

The company is also awaiting a regulatory decision on its multiple myeloma drug Xpovio for a potential indication in myelofibrosis.

Analysts noted that while the extension is not a long-term solution, it provides needed breathing room.

The brief also mentioned Amgen’s interest in expanding the use of Imdelltra in combination with AstraZeneca’s Imfinz, but no further details were provided.